English Journal
- Variation in intravenous iron use internationally and over time: the Dialysis Outcomes and Practice Patterns Study (DOPPS).
- Bailie GR, Larkina M, Goodkin DA, Li Y, Pisoni RL, Bieber B, Mason N, Tong L, Locatelli F, Marshall MR, Inaba M, Robinson BM.Author information Albany Nephrology Pharmacy Group (ANephRx), Albany College of Pharmacy and Health Sciences, Albany, NY, USA.AbstractBACKGROUND: To examine patterns of intravenous (IV) iron use across 12 countries from 1999 to 2011.
- Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.Nephrol Dial Transplant.2013 Oct;28(10):2570-9. doi: 10.1093/ndt/gft062.
- BACKGROUND: To examine patterns of intravenous (IV) iron use across 12 countries from 1999 to 2011.METHODS: Trends in iron use are described among 32 192 hemodialysis (HD) patients in the Dialysis Outcomes and Practice Patterns Study. Adjusted associations of IV iron dose with serum ferritin and tra
- PMID 24078642
- Clinical efficacy of two forms of intravenous iron--saccharated ferric oxide and cideferron--for iron deficiency anemia.
- Araki T, Takaai M, Miyazaki A, Ohshima S, Shibamiya T, Nakamura T, Yamamoto K.Author information Department of Pharmacy, Gunma University Hospital, Maebashi, Japan. tkyaraki@gunma-u.ac.jpAbstractOver 90% of iron deficiency anemia cases are due to iron deficiency associated with depletion of stored iron or inadequate intake. Parenteral iron supplementation is an important part of the management of anemia, and some kinds of intravenous iron are used. However, few studies have evaluated the clinical efficacy of these drugs. The purpose of this study was to compare and assess the clinical efficacy of two types of intravenous iron injection, saccharated ferric oxide (SFO) and cideferron (CF). Medical records were obtained for 91 unrelated Japanese anemia patients treated with SFO (n = 37) or CF (n = 54) from May 2005 to May 2010 at Gunma University Hospital. Patients treated with blood transfusion, erythropoietin or oral iron were excluded. Hemoglobin (Hb) values measured on day 0, 7 and 14 were used to assess the efficacy of intravenous irons. A significant increase was observed in the mean Hb value by day 14 of administration in both the CF group and SFO group, and the mean Hb increase due to administration of CF for 7 days was comparable to that of SFO for 14 days. Age and sex did not affect improvement of Hb value. CF is fast acting and highly effective compared with SFO for the treatment of iron deficiency anemia. The use of CF may shorten a therapeutic period for iron deficiency anemia, and CF may be feasible for reducing the hospitalization period.
- Die Pharmazie.Pharmazie.2012 Dec;67(12):1030-2.
- Over 90% of iron deficiency anemia cases are due to iron deficiency associated with depletion of stored iron or inadequate intake. Parenteral iron supplementation is an important part of the management of anemia, and some kinds of intravenous iron are used. However, few studies have evaluated the cl
- PMID 23346769
- [MR lymphography: first application to human].
- Okuhata Y, Xia T, Urahashi S, Arimizu N.Author information Department of Radiology, Nihon University School of Medicine.AbstractFirst clinical trial of MR lymphography is described. The subjects were two normal volunteers. The contrast agent was cideferron, which was an iron colloid. We obtained MR images of the inguinal lymph nodes before and after subcutaneous injection of the agent in the dorsal feet. As a result, the signal intensities on T2 weighted images remarkably decreased at two hours after injection and kept low until three months after. Although pigmentation around the injection site was observed, it was gradually fading within six months. In conclusion, MR lymphography with cideferron can be applied clinically.
- Nihon Igaku Hōshasen Gakkai zasshi. Nippon acta radiologica.Nihon Igaku Hoshasen Gakkai Zasshi.1994 Apr 25;54(5):410-2.
- First clinical trial of MR lymphography is described. The subjects were two normal volunteers. The contrast agent was cideferron, which was an iron colloid. We obtained MR images of the inguinal lymph nodes before and after subcutaneous injection of the agent in the dorsal feet. As a result, the sig
- PMID 8190610
Japanese Journal
- 腎性貧血に投与した3種類の静注用鉄剤の治療効果の比較検討
- 今田 直樹,清水 輝記,大西 彰 [他],森田 壮平,森 優,小山 正樹,青木 正,畑 佳伸,田中 善之
- 日本透析医学会雑誌 = Journal of Japanese Society for Dialysis Therapy 41(4), 237-243, 2008-04-28
- 血液透析患者の貧血の治療には静注用鉄剤と遺伝子組み換えヒトエリスロポエチン（rHuEPO）の投与が重要である．鉄剤については効果に差がないと一般的に考えられている．しかし，当院では静注用鉄剤を含糖酸化鉄からシデフェロンに変えた時に変化がおこることを経験している．認められた変化は予想を上回る血清フェリチン値の上昇，鉄剤の投与量およびrHuEPO投与量の減少であった．今回，同一患者に3種類の静注用鉄剤 …
- NAID 10021274401
Related Links
- Cideferron is a medicine available in a number of countries worldwide. A list of US medications equivalent to Cideferron is available on the Drugs.com website. ... Important Notice: The Drugs.com international database is in BETA ...
- Find quality suppliers and manufacturers of CIDEFERRONfor price inquiry.where to buy CIDEFERRON.Also offer free database of CIDEFERRON including MSDS sheet(poisoning, toxicity, hazards and safety),chemical properties ...
Related Pictures
★リンクテーブル★
| リンク元 | 「シデフェロン」 |
「シデフェロン」
- 英
- cideferron
- 商
- フェリコン